Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells

被引:41
作者
Reinhold, William C.
Reimers, Mark A.
Maunakea, Alika K.
Kim, Sohyoung
Lababidi, Samir
Scherf, Uwe
Shankavaram, Uma T.
Ziegler, Micah S.
Stewart, Claudia
Kouros-Mehr, Hosein
Cui, Hengmi
Dolginow, Douglas
Scudiero, Dominic A.
Pommier, Yves G.
Munroe, David J.
Feinberg, Andrew P.
Weinstein, John N.
机构
[1] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH,Genom & Bioinformat Grp, Bethesda, MD 20892 USA
[2] Gene Logic, Gaithersburg, MD USA
[3] NCI, Sci Applicat Int Corp, Frederick Inc, Frederick, MD 21701 USA
[4] Johns Hopkins Univ, Sch Med, Dept Med, Epigenet Unit, Baltimore, MD 21205 USA
关键词
INVASION-SUPPRESSOR GENE; CPG ISLAND METHYLATION; BREAST-CANCER; MOLECULAR PHARMACOLOGY; PROSTATE-CANCER; MALIGNANT PROGRESSION; MULTIDRUG-RESISTANCE; EXPRESSION DATABASE; GASTRIC-CANCER; DRUG SCREEN;
D O I
10.1158/1535-7163.MCT-06-0609
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
E-cadherin (E-cad) is a transmembrane adhesion glycoprotein, the expression of which is often reduced in invasive or metastatic tumors. To assess E-cad's distribution among different types of cancer cells, we used bisulfite-sequencing for detailed, base-by-base measurement of CpG methylation in E-cad's promoter region in the NCI-60 cell lines. The mean methylation levels of the cell lines were distributed bimodally, with values pushed toward either the high or low end of the methylation scale. The 38 epithelial cell lines showed substantially lower (28%) mean methylation levels compared with the nonepithelial cell lines (58%). The CpG site at -143 with respect to the transcriptional start was commonly methylated at intermediate levels, even in cell lines with low overall DNA methylation. We also profiled the NCI-60 cell lines using Affymetrix U133 microarrays and found E-cad expression to be correlated with E-cad methylation at highly statistically significant levels. Above a threshold of similar to 20% to 30% mean methylation, the expression of E-cad was effectively silenced. Overall, this study provides a type of detailed analysis of methylation that can also be applied to other cancer-related genes. As has been shown in recent years, DNA methylation status can serve as a biomarker for use in choosing therapy.
引用
收藏
页码:391 / 403
页数:13
相关论文
共 62 条
[1]   Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance [J].
Annereau, JP ;
Szakacs, G ;
Tucker, CJ ;
Arciello, A ;
Cardarelli, C ;
Collins, J ;
Grissom, S ;
Zeeberg, BR ;
Reinhold, W ;
Weinstein, JN ;
Pommier, Y ;
Paules, RS ;
Gottesman, MM .
MOLECULAR PHARMACOLOGY, 2004, 66 (06) :1397-1405
[2]  
Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO
[3]  
2-D
[4]   CLONING AND CHARACTERIZATION OF THE HUMAN INVASION SUPPRESSOR GENE E-CADHERIN (CDH1) [J].
BERX, G ;
STAES, K ;
VANHENGEL, J ;
MOLEMANS, F ;
BUSSEMAKERS, MJG ;
VANBOKHOVEN, A ;
VANROY, F .
GENOMICS, 1995, 26 (02) :281-289
[5]   E-cadherin is a tumour invasion suppressor gene mutated in human lobular breast cancers [J].
Berx, G ;
CletonJansen, AM ;
Nollet, F ;
deLeeuw, WJF ;
vandeVijver, MJ ;
Cornelisse, C ;
vanRoy, F .
EMBO JOURNAL, 1995, 14 (24) :6107-6115
[6]  
BOYD M, 1989, CANC PRINCIPLES PRAC, V3
[7]   Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel [J].
Bussey, KJ ;
Chin, K ;
Lababidi, S ;
Reimers, M ;
Reinhold, WC ;
Kuo, WL ;
Gwadry, F ;
Jain, A ;
Kouros-Mehr, H ;
Fridlyand, J ;
Jain, A ;
Collins, C ;
Nishizuka, S ;
Tonon, G ;
Roschke, A ;
Gehlhaus, K ;
Kirsch, I ;
Scudiero, DA ;
Gray, JW ;
Weinstein, JN .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :853-867
[8]   The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene [J].
Christofori, G ;
Semb, H .
TRENDS IN BIOCHEMICAL SCIENCES, 1999, 24 (02) :73-76
[9]   DNA methylation and gene silencing in cancer: which is the guilty party? [J].
Clark, SJ ;
Melki, J .
ONCOGENE, 2002, 21 (35) :5380-5387
[10]  
Corn PG, 2000, CLIN CANCER RES, V6, P4243